Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
Master degree with a specialization in finance Passed the 3 level of the CFA exam. May be eligible to become CFA charterholder upon completion of the required work experience. Currently 2 years in the investment industry as a portfolio manager assistant and fund manager
Hedge Fund Insights is a premium service tailored to long-term oriented value investors. We provide subscribers with detailed idea analysis, real-time trade updates, and portfolio composition.
"It's like having your own hedge fund analyst."
Our TipRank profile: https://www.tipranks.com/bloggers/hfi
David Stockman is the ultimate Washington insider turned iconoclast. He began his career in Washington as a young man and quickly rose through the ranks of the Republican Party to become the Director of the Office of Management and Budget under President Ronald Reagan. After leaving the White House, Stockman had a 20-year career on Wall Street.
At the podium, Stockman’s expertise and experience cannot be matched, and he has a reputation for zesty financial straight talk. Defying right- and left-wing boxes, his latest book catalogues both the corrupters and defenders of sound money, fiscal rectitude, and free markets. Stockman discusses the forces that have left the public sector teetering on the edge of political dysfunction and fiscal collapse and have caused America’s financial system to morph into an unstable, bubble-prone gambling arena that undermines capitalist prosperity and showers speculators with vast windfall gains.
Stockman’s career in Washington began in 1970, when he served as a special assistant to U.S. Representative, John Anderson of Illinois. From 1972 to 1975, he was executive director of the U.S. House of Representatives Republican Conference. Stockman was elected as a Michigan Congressman in 1976 and held the position until his resignation in January 1981.
He then became Director of the Office of Management and Budget under President Ronald Reagan, serving from 1981 until August 1985. Stockman was the youngest cabinet member in the 20th century. Although only in his early 30s, Stockman became well known to the public during this time concerning the role of the federal government in American society.
After resigning from his position as Director of the OMB, Stockman wrote a best-selling book, The Triumph of Politics: Why the Reagan Revolution Failed (1986). The book was Stockman’s frontline report of the miscalculations, manipulations, and political intrigues that led to the failure of the Reagan Revolution. A major publishing event and New York Times bestseller in its day, The Triumph of Politics is still startlingly relevant to the conduct of Washington politics today.
After leaving government, Stockman joined Wall Street investment bank Salomon Bros. He later became one of the original partners at New York-based private equity firm, The Blackstone Group. Stockman left Blackstone in 1999 to start his own private equity fund based in Greenwich, Connecticut.
In his newest New York Times best-seller, The Great Deformation: The Corruption of Capitalism in America (2013), Stockman lays out how the U.S. has devolved from a free market economy into one fatally deformed by Washington’s endless fiscal largesse, K-street lobbies and Fed sponsored bailouts and printing press money.
Stockman was born in Ft. Hood, Texas. He received his B.A. from Michigan State University and pursued graduate studies at Harvard Divinity School.
He lives in Greenwich, Connecticut, with his wife Jennifer Blei Stockman. They have two daughters, Rachel and Victoria.
I am the author of Alternative Assets and Strategic Allocation, released in 2010 by Bloomberg Press/John Wiley. I have been involved with investments of all types on both sides of the Atlantic since 1980, as an equity analyst, portfolio manager, research director and corporate planner. I have established the investment function at several firms and introduced alternative investments where they had not previously been employed. I was deeply involved with shaping European Union securities legislation and have consulted widely to investment management firms, central banks and ministries of finance. I am also the author of articles appearing in the Journal of Risk Finance and the Journal of Trading. I hold a Ph.D. in philosophy from Yale University.
Learning as I go. My investing experience is limited, but I believe that biotechnology/pharmaceuticals hold the key to the best returns in the next 5-10 years. Targeted therapy, monoclonal antibodies, and genetic treatment tailoring are the future of medicine.
I am a practicing Army Physician (Diagnostic Radiologist). My professional interests include neuroradiology, brain tumors, head and neck cancer, functional MRI, and emerging tagged imaging agents. I intend to apply for a fellowship in neuroradiology this coming Summer. As such, I intend my writing to be speculative, but directed by science and my experiences thus far in medicine with an optimistic essence.
Jake V. is a hedge fund manager in Georgia. He attended Princeton University during undergrad, and now works for a $4B AUM long/short global equity fund. His expertise include understanding the global economic environment, and positioning a portfolio to withstand the various cycles.
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
Mr. Andres has spent the last 40 years as an innovator and leader in the world of fixed income investments. His leadership experiences across the broad spectrum of both tax-exempt and taxable products are unique and underscore the depth of understanding he offers in support of fixed income investors. He has played an active role in managing assets in fluid economic conditions – during both rising and declining rate environments – and in the face of rising geo-political events. His Wall Street career highlights include: National Sales Manager for Municipal Securities at Kidder Peabody; National Sales Manager at Merrill Lynch where he led Merrill’s efforts to finance both the Dallas-Fort Worth Airport and the Meadowlands Sports Complex; Director of Taxable Credit and Underwriting at Merrill, with responsibility for positioning, hedging, and risk management; and President – Merrill Lynch Mortgage Capital Corporation, with responsibility for all mortgage-backed securities trading, hedging, research, and investment banking.
He utilized these leadership positions as a platform to further enhance the development of the modern bond market. Under Bob’s leadership Merrill Lynch underwrote the first billion dollar collateralized mortgage obligation (CMO), and he played a pivotal role in the development and growth of the “Tiger” product – the forerunner of all zero coupon securities. He received public recognition for introducing sophisticated hedging techniques to improve trading profitability. It was at this time that Institutional Investor featured Bob as one of three fixed income industry leaders.
Bob’s post-Wall Street career began when he co-founded Martindale Andres & Company, a buy-side investment management organization focused on fixed income and small cap equities. He functioned as the firm’s President and Chief Investment Officer of Fixed Income, overseeing $1.2 billion in fixed income assets. Subsequently, Bob served as Chief Investment Strategist for Envestnet, a publicly traded investment solutions company serving more than 36,000 investment advisors and overseeing nearly $700 billion in assets. He is also the founder and editor of the Andres Review, a publication that seeks to provide intellectually honest and impartial economic and market commentary. His writings have gained wide distribution within the advisor community.
Bob’s unique perspective and ability to explain the economic landscape and the arcane world of fixed income has gained him national recognition with the media. His has been featured in Barron’s, Institutional investor, and has appeared regularly on CNBC, Fox Business, and Bloomberg.
Bob attended Columbia University where he studied Political Science and Economics.
Keith began his career as a research scientist (developmental biology, biochemistry, molecular biology) at the Australian National University, University of Oxford (UK), the Max Planck Institute for Biochemistry (Munich, Germany) and finally Macquarie University (Sydney) where he held a Chair in Biology and established the Centre for Analytical Biotechnology. Pioneering the area of proteomics (with Marc Wilkins in his group coining the term), Keith established the world’s first government-funded Major National Proteomics Facility (Australian Proteome Analysis Facility) which was involved with industrialising protein science.
Keith left academe with his team to found Proteome Systems Ltd in 1999 to commercialise proteomics. The company had a strong focus on intellectual property, engineering/technology and bioinformatics. As CEO he led the company to ASX listing in 2004. Since 2005 Keith has been involved in new business development in biotech, e-health and other emerging technologies. Keith sees climate change and sustainable development as a major issue for humankind and also a major business disruptor/risk and opportunity.
Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering.
With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. He is not a financial advisor but his perspective adds relevance to decision-making concerning feasibility and investment in technology innovation.
Abigail F. Doolittle is the founder of Peak Theories Research LLC, which is an on-line research firm dedicated to providing investors with a technically-inclined view on the financial markets and the economy. The firm’s research begins with the analysis of charts and then ties in various economic fundamentals to better understand the trends pointed to in the charts. She has more than 12 years of experience in the financial services industry including portfolio management, macro research, institutional equity sales, and investment banking.
Abigail F. Doolittle
Peak Theories Research LLC
Biomed Group is an independent research group, with a goal of providing investors with real-time information and exclusive specialised research on biotechnology stocks, so that they can make informed investment decisions.
Dean, School of Business and Professor of Marketing at The College of New Jersey. Co-author with Peter Vander Nat, a senior economist at the FTC, of 2002 and 2014 journal articles on pyramid schemes and multilevel marketing. Also served as an expert witness in the prosecution of pyramid schemes, including Gold Unlimited, brought by the US Department of Justice, and International Heritage Inc, at the time the largest pyramid scheme prosecuted by the SEC.
Frank Holmes is CEO and chief investment officer of U.S. Global Investors, Inc., a boutique investment advisory firm based in San Antonio that manages domestic and offshore funds specializing in the natural resources and emerging markets sectors. The company’s no-load mutual funds include the Global Resources Fund (PSPFX), the World Precious Minerals Fund (UNWPX) and the Gold and Precious Metals Fund (USERX). For more insight and perspective from Mr. Holmes, please visit his investment blog, “Frank Talk” (http://www.usfunds.com/investor-resources/frank-talk/).
I lecture in Finance in Trinity College, Dublin and at Monterey Institute for International Studies (California) and hold a number of non-Executive and advisory positions. I am research-active in macroeconomics and finance, as well as economic policy analysis and my academic record can be found on the designated section of my blog http://trueeconomics.blogspot.com/. In the past, I served as the Head of Research and Partner with St Columbanus AG, Head of Macroeconomics (Institute for Business Value, IBM), Director of Research (NCB Stockbrokers), Group Editor and Director (Business and Finance Publications). All opinions expressed are my own and do not reflect the views or positions of any of my past, present or future employers. Potential conflicts of interest are highlighted in the posts wherever I can reasonably foresee such arising.
Daniel Tsang, an independent aviation analyst, has established Aspire Aviation, which is formerly known as Airways Aviation News in July 2008.
Daniel Tsang has earned his name and reputation since then for his insightful coverages and his provocative stances in some times.
Daniel Tsang’s research on Chinese carriers was also published in the March 2011 issue of “Orient Aviation“, which was distributed as bonus copies at the Asian Aerospace 2011 in Hong Kong.
Daniel is extensively quoted by news publications and various kinds of media, including:
Agence France Presse (June 2011, August 2014, December 2014, January 2015, February 2015)
Flightglobal (October 2011)
King5 News (October 2011)
The News Tribune (October 2011, December 2014)
Flight International (October 2011)
USA Today (November 2011)
Puget Sound Business Journal (March 2012)
HeraldNet (October 2012, January 2015)
The Seattle Times (November 2012, December 2012)
Bloomberg Businessweek (October 2013)
The Wall Street Journal (December 2013, July 2014)
South China Morning Post (December 2013)
The Business Traveller (April 2014)
The Gulf News (April 2014)
Forbes (June 2014)
The National (July 2014, September 2014)
CNN Money (July 2014)
TIME (July 2014)
Air International (November 2014)
Business Standard (December 2014)
Deutsche Welle (February 2015)
Australian Financial Review (March 2015)
Sydney Morning Herald (March 2015)
Deloitte “2012 Global aerospace and defense industry outlook: A tale of two industries” (March 2012)
RTHK Radio 3 “Money for Nothing” (March 2013)
Panel moderator, The 3rd China International Air Routes Summit 2013, Shenzhen, China (September 2013)
ABC News “The World” (April 2014, July 2014)
Speaker, Airline Retail Conference Asia/Pacific 2015, Hong Kong (February 2015)
Follow Daniel Tsang at @aspireaviation on Twitter.
Dallas currently owns and operates as CEO an Austin-based enterprise consulting firm that specializes in private company lifecycle management, up to and including taking companies public, and in helping consult publicly traded companies ranging in market cap from $100 million to $500 million. He has a specialization in deal flow management and is often the referring and closing source of Joint Ventures and broader M&A. Dallas often works directly with management teams and Boards of microcap and stressed equity companies in which he or members of his professional network are heavily invested. This includes helping with overall strategy, helping with capital structure management, helping facilitate liquidity, helping facilitate Joint Ventures and broader M&A, and helping restructure the business segments if necessary. Recently Dallas has been interviewed by The Pittsburgh Business Times, The Banker, Columbus Business First, Houston Business Journal, The Deal, Energy Intelligence, and his tweets have been used by CNBC to highlight hot button issues regarding Carl Icahn, Bill Ackman, Nelson Peltz’s takeover attempts at DuPont, etc. Dallas has also been quoted and sourced to by StreetSweeper.org, Marcellus.com, MarcellusDrilling.com, Bakken.com, OilOnline.com, and other physical and online publications. "One place of great inefficiency is in the stressed equity markets – or the markets in which a company appears as bankruptcy or a breakup is inevitable. As equities become stressed they often sell down to absurd levels of value that present, should there be value to be unlocked, opportunities for “venture level” returns. These often range in the 3X-10X range. With my unique ability to actually improve business outcomes by working directly with a company and management/Board I’m in a position, should I view the underlying business as salvageable, to directly improve the long-term viability of the company. I am NOT simply an investor in these names but an acting consultant. This allows me to “overlay my network” and to move the company away from a stressed or defaulting outcome and into an outcome probability that allows the equity price to move substantially higher. Identifying these opportunities has generated shareholders and investors thousands of percentage points in aggregate and is something I’m often recognized by paying subscribers for."
Founder and Lead Analyst at Lone Wolf Publications Ltd (www.lonewolftrader.com).
I also manage a private investment portfolio full time, and also provide mutual fund analysis and buy recommendations to individual investors managing their own investments.
I trade for myself via ETFs and futures markets, with interests in commodities generally and a special interest in precious metals.
I apologize to investors who follow my articles, but I no longer expect to submit the newer articles I previously mentioned as forthcoming. I don't currently plan to resume any involvement with SA, though that may eventually change, if the site ever implements/enforces deterrents to web stalkers. For now, I only publicly share opinions on stocks via Twitter, StockTwits, etc. The rest of what follows is my normal profile, so I won't have to rewrite it, should I ever continue posting on SA. Best of luck investing. Cheers. I run a small family office managing long-term portfolios and special projects beyond the capital markets. I'm fortunate to have worked for a NYSE-traded financial firm for the decade through 2010, but I am not an adviser, my articles only share our investing actions/opinions, and they are not investment advice. Proof is in the pudding, so here are our stock portfolio returns from the most recent five years: 2012 +32%, 2013 +52%, 2014 +11%, 2015 +14%, and 2016H1 +12.7% (those are just capital gains, but all holdings pay dividends). Returns are moderating as expected, since most positions were rebuilt/opened in 2010-2012 at extreme undervaluation levels, yet only a few new positions have been opened each of the last few years at moderate undervaluation levels. I also trade around core positions for short-term profits, but I do not include trade gains in portfolio return tracking, and my articles are strictly about long-term investing. My investing career started in the 1980s, and the transition to full-time was finalized in 2009. I only list returns from 2012 because that's when I became most active on SA, and calls can be verified here. For 2008-2011, my focus was shorter-term trades, which made total annual returns harder to tally, so without wasting time backtracking, I can only say returns were worthwhile. For most years prior, I was a blue-chip-only, buy-and-hold guy, which also worked well, so I still own most of those stocks in accounts separate from our actively-managed portfolios.
I am a retiree who now enjoys analyzing and working with stock investments. The Biotech and Healthcare sectors particularly appeal to me both because they discover new solutions to urgent medical needs and can be financially rewarding.
Prior to becoming involved with my current interests, I worked as a Business Analyst for thirty years in New York City where I analyzed a variety of businesses before they received financing. In addition, I reviewed startup firms prior to their receiving investment.
Kristina Hooper, CFP, CAIA, CIMA, ChFC, is the US Investment Strategist and Head of US Capital Markets Research & Strategy with Allianz Global Investors. She has a B.A. from Wellesley College, a J.D. from Pace Law and an M.B.A. in finance from NYU, where she was a teaching fellow in macroeconomics.
CrossBorder Capital provides asset allocation research based on the monitoring of cross-border capital flows. The firm publishes regular assessments of the liquidity risk environment across 80 economies Worldwide and produces the GLI monthly series of Global Liquidity Indexes that track liquidity flows around the World.
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
I am the investment manager for Darkravenwind LLC, a small software development consulting firm. 20% of our pre-tax revenue is my responsibility to invest and grow. I also help moderate the "Value Investing" group on Facebook. My hobbies include fighting the Fed, martial arts, and old video games.
I have been using value investing techniques as first described by Benjamin Graham since approximately 2006. I was wasting my life up to that point. My specialty, over and above corporate valuation, is analyzing people. Human behavior is remarkably consistent and can lead to huge gains when you understand what motivates them.
In my own portfolio I have a diversified income focus with a preference for long term earnings and dividend growth. When a good opportunity comes along, I'll focus a large percentage of assets into that single holding. I'm also maintaining an income portfolio with a little over 180 high yielding companies as a bit of an experiment.
I have been mostly self taught, but I am also working on obtaining a finance degree. Quadrupled my money in the 2008 crash, by 2012 my total portfolio was over 50,000% higher than when I had first started.
I was a previous employee at Countrywide Financial Corp., and was present during the mortgage meltdown. I saw firsthand how the company was falling apart from the inside while management continued to believe the organization could be rescued. I have made bond analysis and studying the effects of inflation an additional specialty of mine.
Market direction is irrelevant. I look for value. Profitable companies that are low or even fairly priced, so long as the results are dependable. Intrinsic value is subjective, but earnings power matters. The current dividend yield, and the number of competitors are strong factors in my decisions. I am absolutely fearless of the future and do not make political views a part of my investment process.
I additionally make frequent updates to a blog maintainted at WhoTrades called "Brand Power", you can read and subscribe to it at bandpower.whotrades.com. Live trading data on my purchases should be available at some point in the near future.
Paul Franke is a private investor and speculator with nearly 30 years of trading experience, including investment management. Mr. Franke was Editor and Publisher of the Maverick Investor® newsletter during the 1990s, widely quoted by CNBC®, Barron’s®, the Washington Post® and Investor’s Business Daily®. Paul was consistently ranked among top investment advisors nationally for stock market and commodity macro views by Timer Digest® during the 1990s. Mr. Franke was ranked #1 in the Motley Fool® CAPS stock picking contest during parts of 2008 and 2009, out of 60,000+ portfolios. Mr. Franke was Director of Research at Quantemonics Investing® from 2010-13, running several model portfolios on the Covestor.com mirror platform (including the least volatile, lowest beta, fully-invested equity portfolio on the site).
Seeking Alpha articles will focus on undervalued blue-chip companies or leaders in their industry. A contrarian stock picking style, along with weekly algorithm analysis of fundamental and technical data have been developed into a system for finding stocks, nicknamed the “Victory Formation.” Supply/demand imbalances signaled by specific stock price and volume movements are a critical part of this formula for success. Mr. Franke suggests investors use 10% or 20% stop-loss levels on individual choices and a diversified approach of owning 20-30 undervalued, unappreciated, turnaround favorites to achieve regular stock market outperformance.
Convergence Investment Management is a Registered Investment Advisory firm that focuses on unique opportunities within the Closed-End Fund and Exchange Traded Fund marketplaces. We believe that the markets, while very efficient, are not perfectly efficient and that opportunities for superior risk adjusted returns exist for those willing to put in the work to identify short-term price dislocations. Charles “Chad” Gray is Convergence Investment Management’s Portfolio Manager. Prior to launching Convergence, Mr. Gray spent much of professional his career in Silicon Valley developing better data analytics platforms and data management techniques, many of which have been applied to the Convergence approach. Mr. Gray earned both an M.B.A. and M.S. in Electrical Engineering from Massachusetts Institute of Technology, and a B.S. in Engineering from Northwestern University. He has also earned the CFA designation and is an active member with the CFA Society of San Francisco.
Ms. Williams is a Certified Public Accountant whose writing will focus on analyzing financial statements and their implications for investors. She holds an MBA from the University of Miami and a BA from the University of Virginia.
Albert Sung is the author of Correlation Economics, monitoring breaking economic news on a day to day basis.
He started investing in 2008 because of the economic crisis and holds a masters degree in chemical engineering. Previously, he worked several years as a process engineer at Ashland, a competitor of Dow Chemical. Today, he works as a regulatory compliance consultant at J&J, but his real passion will stay in macro-economics.
His experience in the chemical and pharmaceutical industry allows him to monitor the economy from a process engineering standpoint, analyzing macro-economic charts, correlations and trends.